What This Means
This research investigated how a traditional Chinese medicine product called Ludangshen oral liquid (LDSKFY), used clinically to treat chronic kidney inflammation, works against nephrotic syndrome — a serious kidney disorder characterized by excessive protein loss in urine, swelling, and impaired kidney function. The researchers used a combination of advanced chemical analysis, computer-based drug network predictions, animal experiments, cell culture experiments, and gut bacteria analysis to piece together how LDSKFY affects the disease at multiple levels. They identified 20 active chemical components in LDSKFY and found that these components appear to work primarily by blocking a biological signaling pathway called TGF-β1/Smad3, which is known to drive kidney scarring and damage. In rats with adriamycin-induced kidney disease, LDSKFY treatment improved multiple measures of kidney health, including reducing protein in the urine, normalizing cholesterol and blood lipid levels, and reducing markers of kidney failure like creatinine and urea nitrogen. In kidney cells grown in the laboratory, LDSKFY helped restore the normal architecture of specialized kidney filter cells (podocytes) and reduced signs of fibrosis (scarring).
Beyond the kidney-specific effects, this research also suggests that LDSKFY influences the gut microbiome — the community of bacteria living in the intestines — by promoting a more stable bacterial community in treated animals. This finding points to a potential gut-kidney connection in how LDSKFY works. Computer modeling confirmed that several of LDSKFY's active chemical components can physically bind to and interact with the key proteins in the TGF-β1/Smad3 pathway (TGF-β1, Smad3, and Smad7), providing a molecular explanation for the observed biological effects.
This research suggests that LDSKFY works through multiple simultaneous mechanisms — primarily by dampening harmful kidney fibrosis signals and also by reshaping gut bacterial communities — rather than through a single drug target. These findings provide a scientific framework for understanding why this traditional medicine may be effective for kidney disease and could support its broader clinical use for nephrotic syndrome and chronic kidney inflammation, though further clinical studies in humans would be needed to confirm these effects.